Focused On-demand Library for Small ribosomal subunit protein mS35

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P82673

UPID:

RT35_HUMAN

Alternative names:

28S ribosomal protein S28, mitochondrial; 28S ribosomal protein S35, mitochondrial

Alternative UPACC:

P82673; Q32LZ1; Q6P4C6; Q7L1M6; Q8NBP4; Q96AI0; Q9H044; Q9HC14; Q9P1R5

Background:

Small ribosomal subunit protein mS35, also known as 28S ribosomal protein S28 and S35, mitochondrial, plays a crucial role in the mitochondrial ribosome. It is part of the small ribosomal subunit, essential for protein synthesis within mitochondria, highlighting its significance in cellular energy metabolism and overall cellular function.

Therapeutic significance:

Understanding the role of Small ribosomal subunit protein mS35 could open doors to potential therapeutic strategies. Its pivotal function in mitochondrial protein synthesis positions it as a key player in cellular health and disease management.